In an interview that took place at the European Society for Medical Oncology 2024 Congress in Barcelona, Spain, Timothy Yap, MBBS, PhD, medical oncologist, The University of Texas…
Kidney cancer affects over 80,000 Americans annually, with renal cell carcinoma as the dominant type. Benjamin R. Lee, MD, MBA, outlines current AUA guideline recommendations, including when to…
NEW YORK (Reuters Health) – After first-line treatment with bevacizumab plus interferon-alpha2a, subsequent therapy with tyrosine kinase inhibitors (TKIs) improves survival in patients with metastatic renal cell carcinoma,…
NEW YORK (Reuters Health) – High-dose chemo followed by autologous stem-cell transplantation achieves good results in patients with relapsed Hodgkin’s lymphoma, and outcomes are not improved by additional…
NEW YORK (Reuters Health) – In order to minimize the risk of potential harms, erythropoiesis-stimulating agents (ESAs) in patients undergoing myelosuppressive chemotherapy should be administered at the lowest…
NEW YORK (Reuters Health) – Adding the anti-VEGF monoclonal antibody bevacizumab to state-of-the-art adjuvant chemotherapy for stage II or III colon cancer does not improve disease-free survival, according…
NEW YORK (Reuters Health) – Rofecoxib used as adjuvant therapy does not improve survival or reduce recurrences in patients who have undergone surgery for colorectal cancer, according to…
NEW YORK (Reuters Health) – Adding interferon alpha-2b and megadose vitamins to treatment with intravesical BCG does not improve outcomes in patients with non-muscle invasive bladder cancer. In…
NEW YORK (Reuters Health) – The tyrosine-kinase inhibitor pazopanib seems to be a promising option for treating progressive metastatic differentiated thyroid cancer that is unresponsive to radioiodine therapy,…
NEW YORK (Reuters Health) – Response rates are higher when bortezomib plus dexamethasone rather than vincristine plus doxorubicin plus dexamethasone (VAD) is used as induction therapy before stem-cell…
NEW YORK (Reuters Health) – Men whose baseline PSA is less than 2.0 ng/mL are unlikely to benefit from further screening for prostate cancer, according to findings reported…
NEW YORK (Reuters Health) – A finding of homozygosity for mutations that cause Gaucher disease in patients who report no symptoms of the disorder warrants further followup. Manifestations…
